Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 3
1990 1
1991 2
1992 7
1993 10
1994 14
1995 10
1996 12
1997 27
1998 67
1999 110
2000 128
2001 164
2002 207
2003 316
2004 419
2005 493
2006 638
2007 653
2008 794
2009 1011
2010 1151
2011 1181
2012 1148
2013 1211
2014 1080
2015 1015
2016 1042
2017 949
2018 906
2019 932
2020 967
2021 908
2022 868
2023 815
2024 746
2025 164

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17,833 results

Results by year

Filters applied: . Clear all
Page 1
Clopidogrel Pharmacogenetics.
Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, Goodman SG, Weinshilboum RM, Wang L, Baudhuin LM, Lerman A, Hasan A, Iturriaga E, Fu YP, Geller N, Bailey K, Farkouh ME. Pereira NL, et al. Circ Cardiovasc Interv. 2019 Apr;12(4):e007811. doi: 10.1161/CIRCINTERVENTIONS.119.007811. Circ Cardiovasc Interv. 2019. PMID: 30998396 Free PMC article. Review.
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel …
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional …
The Role of Clopidogrel in 2020: A Reappraisal.
Patti G, Micieli G, Cimminiello C, Bolognese L. Patti G, et al. Cardiovasc Ther. 2020 Mar 16;2020:8703627. doi: 10.1155/2020/8703627. eCollection 2020. Cardiovasc Ther. 2020. PMID: 32284734 Free PMC article. Review.
Deescalation of DAPT by switching from prasugrel or ticagrelor to clopidogrel may be required in some patients with ACS. Furthermore, real-world studies of ACS patients have not confirmed the benefits of the newer P2Y(12) inhibitors over clopidogrel. In patients wit …
Deescalation of DAPT by switching from prasugrel or ticagrelor to clopidogrel may be required in some patients with ACS. Furthermore, …
Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.
Valgimigli M, Gragnano F, Branca M, Franzone A, da Costa BR, Baber U, Kimura T, Jang Y, Hahn JY, Zhao Q, Windecker S, Gibson CM, Watanabe H, Kim BK, Song YB, Zhu Y, Vranckx P, Mehta S, Ando K, Hong SJ, Gwon HC, Serruys PW, Dangas GD, McFadden EP, Angiolillo DJ, Heg D, Calabrò P, Jüni P, Mehran R; Single Versus Dual Antiplatelet Therapy (Sidney-3) Collaboration. Valgimigli M, et al. JAMA Cardiol. 2024 May 1;9(5):437-448. doi: 10.1001/jamacardio.2024.0133. JAMA Cardiol. 2024. PMID: 38506796
Trials of ticagrelor monotherapy were conducted in Asia, Europe, and North America; trials of clopidogrel monotherapy were all conducted in Asia. Ticagrelor was noninferior to DAPT for the primary end point (HR, 0.89; 95% CI, 0.74-1.06; P for noninferiority = .004), but …
Trials of ticagrelor monotherapy were conducted in Asia, Europe, and North America; trials of clopidogrel monotherapy were all conduc …
P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition.
Chen J, Tang Y, Zhong Y, Wei B, Huang XR, Tang PM, Xu A, Lan HY. Chen J, et al. Mol Ther. 2022 Sep 7;30(9):3017-3033. doi: 10.1016/j.ymthe.2022.06.019. Epub 2022 Jul 5. Mol Ther. 2022. PMID: 35791881 Free PMC article.
Clopidogrel, a P2Y12 inhibitor, is a novel anti-fibrosis agent for chronic kidney disease (CKD), but its mechanisms remain unclear, which we investigated by silencing P2Y12 or treating unilateral ureteral obstruction (UUO) in LysM-Cre/Rosa Tomato mice with clopidogrel …
Clopidogrel, a P2Y12 inhibitor, is a novel anti-fibrosis agent for chronic kidney disease (CKD), but its mechanisms remain unclear, w …
Dual therapy with clopidogrel and rivaroxaban in cats with thromboembolic disease.
Lo ST, Walker AL, Georges CJ, Li RH, Stern JA. Lo ST, et al. J Feline Med Surg. 2022 Apr;24(4):277-283. doi: 10.1177/1098612X211013736. Epub 2021 May 10. J Feline Med Surg. 2022. PMID: 33966532 Free PMC article.
Current American College of Veterinary Internal Medicine guidelines recommend the use of clopidogrel in cats at risk for ATE, with addition of a factor Xa inhibitor in very high risk or post-ATE cases. ...METHODS: The study included 32 cats prescribed clopidogrel (1 …
Current American College of Veterinary Internal Medicine guidelines recommend the use of clopidogrel in cats at risk for ATE, with ad …
Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention.
Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Nishikawa R, Ando K, Ono K, Kadota K, Suwa S, Morishima I, Yoshida R, Hata Y, Akao M, Yagi M, Suematsu N, Morino Y, Yokomatsu T, Takamisawa I, Noda T, Doi M, Okayama H, Nakamura Y, Hibi K, Sakamoto H, Noguchi T, Kimura T; STOPDAPT-2 Investigators. Watanabe H, et al. J Am Coll Cardiol. 2024 Jan 2;83(1):17-31. doi: 10.1016/j.jacc.2023.10.013. Epub 2023 Oct 23. J Am Coll Cardiol. 2024. PMID: 37879491 Free article. Clinical Trial.
OBJECTIVES: This study compared clopidogrel monotherapy following 1 month of DAPT (clopidogrel group) with aspirin monotherapy following 12 months of DAPT (aspirin group) after PCI for 5 years. ...CONCLUSIONS: Clopidogrel might be an attractive alternative to …
OBJECTIVES: This study compared clopidogrel monotherapy following 1 month of DAPT (clopidogrel group) with aspirin monotherapy …
Reply.
Dalén M. Dalén M. Ann Thorac Surg. 2020 Jan;109(1):305. doi: 10.1016/j.athoracsur.2019.05.010. Epub 2019 Jun 15. Ann Thorac Surg. 2020. PMID: 31843131 No abstract available.
Clopidogrel-induced pneumonia.
Tomoda Y, Miyajima T, Nagasawa C, Awaya Y. Tomoda Y, et al. BMJ Case Rep. 2021 Jun 24;14(6):e244564. doi: 10.1136/bcr-2021-244564. BMJ Case Rep. 2021. PMID: 34167966 Free PMC article. No abstract available.
Aspirine ou clopidogrel ? Le débat continue.
Abellan C. Abellan C. Rev Med Suisse. 2023 Apr 12;19(822):739. doi: 10.53738/REVMED.2023.19.822.739. Rev Med Suisse. 2023. PMID: 37057858 French. No abstract available.
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 Investigators. Watanabe H, et al. JAMA. 2019 Jun 25;321(24):2414-2427. doi: 10.1001/jama.2019.8145. JAMA. 2019. PMID: 31237644 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomized either to 1 month of DAPT followed by clopidogrel monotherapy (n=1523) or to 12 months of DAPT with aspirin and clopidogrel (n=1522). ...CONCLUSIONS AND RELEVANCE: Among patients undergoing PCI, 1 month of DAPT followed by …
INTERVENTIONS: Patients were randomized either to 1 month of DAPT followed by clopidogrel monotherapy (n=1523) or to 12 months of DAP …
17,833 results
You have reached the last available page of results. Please see the User Guide for more information.